Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin´s Lymphoma (NHL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01685008 |
|
Recruitment Status :
Active, not recruiting
First Posted : September 13, 2012
Last Update Posted : December 11, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Non-Hodgkin Lymphoma | Drug: MOR00208 (formerly Xmab 5574) | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 92 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase IIa, Open-label, Multicenter Study of Single-Agent MOR00208, an Fc-optimized Anti-CD19 Antibody in Patients With Relapsed or Refractory Non-Hodgkin´s Lymphoma (NHL) |
| Actual Study Start Date : | April 23, 2013 |
| Estimated Primary Completion Date : | December 2020 |
| Estimated Study Completion Date : | December 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: MOR00208 (formerly Xmab5574)
intravenous Infusion of MOR00208, Fc-Optimized Anti-CD19 Antibody
|
Drug: MOR00208 (formerly Xmab 5574)
Other Name: MOR208 |
- Overall response rate (ORR) [ Time Frame: up to 4 years ]Proportion of Patients with Complete Response (CR) or Partial Response (PR)
- Stable Disease (SD) Rate [ Time Frame: up to 4 years ]Proportion of Patients with Stable Disease
- Duration of Response (DoR) [ Time Frame: up to 4 years ]Time from first CR or PR to first documentation of relapse/progression
- Time to Progression (TTP) [ Time Frame: up to 4 years ]Time from first dosing until documentation of progression or death due to lymphoma
- Progression-free Survival (PFS) [ Time Frame: up to 4 years ]Time from first dosing until progression or death due to any case
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- male or female patients ≥ 18 years of age.
-
histologically-confirmed diagnosis according to REAL/WHO classification, of the following B-cell lymphomas :
- FL
- MCL
- DLBCL
- Other indolent NHL (eg, MZL/MALT)
- Patients' NHL must have progressed after at least 1 prior rituximab containing regimen.
-
one site of measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan defined as at least one lesion that measures at least 1.5 × 1.5 cm,
Exception:
For patients with MCL only, patients with nonmeasurable disease but evaluable sites (bone marrow, spleen, peripheral blood, gastrointestinal tract) can be enrolled.
- Patients who have previously received an autologous stem cell transplantation must be at least 4 weeks post-transplant before study drug administration and must have exhibited a full haematological recovery
- discontinued previous monoclonal antibody therapy (except rituximab) or radioimmunotherapy administration for at least 60 days before study drug administration.
- off rituximab for at least 14 days before the screening visit and be confirmed to have either no response or have disease progression after rituximab treatment.
- Patients with DLBCL had a positive [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET) scan at baseline (Cheson response criteria)
- Life expectancy of > 3 months.
- ECOG performance status of < 3.
-
laboratory criteria at screening:
- Absolute neutrophil count (ANC) ≥ 1.0 (1000/mm3)
- Platelet count ≥ 75 × 109/L without previous transfusion within 10 days of first study drug administration
- Haemoglobin ≥ 8.0 g/dL (may have been transfused)
- Serum creatinine < 2.0 x upper limit of normal (ULN)
- Total bilirubin ≤ 2.0 × ULN
- Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN.
- If a female of childbearing potential, a negative pregnancy test must be confirmed before enrolment and use of double-barrier contraception, oral contraceptive plus barrier contraceptive, or confirmation of having undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation.
- If a male, an effective barrier method of contraception must be used during the study and for 3 months after the last dose if the patient is sexually active with a female of childbearing potential.
- able to comply with all study-related procedures, medication use, and evaluations.
- able understand and give written informed consent and comply with the study protocol.
Exclusion Criteria:
- Previous treatment with cytotoxic chemotherapy, immunotherapy, radiotherapy or other lymphoma specific therapy within 14 days before the screening visit or patient has not recovered from side effects of previous lymphoma-specific therapy.
- Treatment with a systemic investigational agent within 28 days before the screening visit.
- Previous treatment with an anti-CD19 antibody or fragments
- Previous allogenic stem cell transplantation.
- Known or suspected hypersensitivity to the excipients contained in the study drug formulation.
- Clinically significant cardiovascular disease or cardiac insufficiency,cardiomyopathy, preexisting clinically significant arrhythmia, acute myocardial infarction within 3 months of enrolment, angina pectoris within 3 months of enrolment.
- Clinical or laboratory evidence of active hepatitis B or hepatitis C 8. History of HIV infection.
9. Any active systemic infection (viral, fungal, or bacterial) requiring active parenteral antibiotic therapy within 4 weeks of study drug administration.
10. Current treatment with immunosuppressive agents other than prescribed corticosteroids (not more than 10-mg prednisone equivalent).
11. Major surgery or radiation therapy within 4 weeks before first study drug administration.
12. Systemic diseases (cardiovascular, renal, hepatic, etc) that would prevent study treatment in the investigator's opinion.
13. History or clinical evidence of central nervous system (CNS), meningeal, or epidural disease, including brain metastasis.
14. Active treatment/chemotherapy for another primary malignancy within the past 5 years 15. Pregnancy or breastfeeding in women and women of childbearing potential not using an acceptable method of birth control.
16. History of noncompliance to medical regimens or patients who are considered potentially unreliable not cooperative
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01685008
Show 26 study locations
| Principal Investigator: | Kristi Blum, MD | Ohio State University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | MorphoSys AG |
| ClinicalTrials.gov Identifier: | NCT01685008 |
| Other Study ID Numbers: |
MOR208C201 2012-002659-41 ( EudraCT Number ) |
| First Posted: | September 13, 2012 Key Record Dates |
| Last Update Posted: | December 11, 2019 |
| Last Verified: | December 2019 |
|
NHL CD19 MOR208 MOR00208 |
Xmab5574 B-Cell Non-Hodgkin´s Lymphoma Fc-optimized Anti-CD19 Antibody Tafasitamab |
|
Lymphoma Lymphoma, Non-Hodgkin Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases |
Immunoproliferative Disorders Immune System Diseases Antibodies Immunoglobulins Immunologic Factors Physiological Effects of Drugs |